Advertisement

After a 50% Gain, Is It Too Late to Buy Biogen?

After a 50% Gain, Is It Too Late to Buy Biogen?

Biogen (NASDAQ: BIIB) investors cheered earlier this week after the biotech company scored a major regulatory victory. The U.S. Food and Drug Administration approved its controversial Alzheimer's drug. Now, some investors are wondering whether it's too late to get in on the Biogen story.